Welcome to our dedicated page for INTERPACE BIOSCIENCES SEC filings (Ticker: IDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpace Biosciences, Inc. filings document material-event disclosures for a thyroid-focused molecular diagnostics company. Recent 8-K reports furnish operating results and financial-condition updates tied to Interpace Diagnostics and its commercial thyroid testing franchise, including disclosures related to ThyGeNEXT and ThyraMIRv2.
The company’s regulatory filings also record capital-structure developments, including repayment of its term loan facility with BroadOak Capital Partners and conversion of Series C Preferred Stock into common stock. These disclosures provide formal records of results releases, Regulation FD communications, debt obligations, equity structure and business updates following the company’s transition away from PancraGEN.
Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.
The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.
Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.
The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.
Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Interpace Biosciences (IDXG) reported Q3 results. Revenue was $8.756 million, down 29% from $12.295 million a year ago, reflecting the April 2025 loss of Medicare coverage for PancraGEN. Gross profit was $5.439 million. Operating income from continuing operations was $1.145 million versus $2.301 million, and net income was $0.911 million versus $1.676 million.
For the nine months, revenue was $29.504 million, down from $34.515 million; operating income was $2.507 million versus $6.047 million; net income was $1.918 million versus $4.821 million. The company recorded $0.7 million in severance and related costs tied to its restructuring plan. Cash and cash equivalents were $1.423 million as of September 30, 2025, with current assets of $9.130 million and current liabilities of $5.945 million. The BroadOak term loan balance was $1.0 million (fair value $0.977 million) with the maturity extended to December 31, 2025 and interest-only payments beginning July 1, 2025. Shares outstanding were 4,428,539 as of November 7, 2025.
Adjusted EBITDA was $1.263 million in Q3 and $3.735 million year-to-date. Management notes continued focus on cost controls, receivable collections, and financing or strategic alternatives following the PancraGEN coverage change.